Skip to main content Skip to navigation

 


PIM

There is a rich emerging research and literature on antimicrobial activity of main-chain polyimidazolium salts, known as PIM (poly-imidazolium). As anti-microbial agents, PIMs have strong advantages over the common anti-bacterial drugs such as antimicrobial peptides (AMP) or the synthetic antimicrobial polymers usually synthesized via free radical polymerisation (FRP) or ring opening polymerisation (ROP). 


While AMPs are regarded as promising candidates for treating multi-drug-resistant bacterial, their use is often limited by generally higher minimum inhibitory concentrations and instability/degradability in complex environments.  FRP and ROP synthetic polymers typically involves large quantities of organic solvents and produce highly toxic products. In addition, these syntheses are hard to scale up and therefore unable to be produced in large quantities. 


PIM is an innovative anti-microbial agent with a new mechanism of action and demonstrate high antimicrobial activity across a broad spectrum of micro-organisms and at the same time exhibit low toxicity to mammalian cells and are also easy and cheap to produce. 


In addition, the rise of multidrug-resistant bacterial pathogens is becoming a global threat to public health, thus driving the relentless search for new and more effective antibiotics. PIM technology, due to its innovative mode of action, has demonstrated that it is bactericidal towards even the extremely antibiotic resistant pathogens (including the WHO high priority pathogen list) and is unlikely to lead to antibiotic resistance (AMR) issues.